YahooSeptember 1, 2026 at 12:03 PM NY3 days ago
bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance
The company is evaluating an additional application for CyPath Lung that could complement CT imaging when monitoring lung cancer survivors for recurrence or new primary cancers. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) is advancing CyPath Lung for potential use in post-treatment lung cancer surveillance, expanding its focus beyond early detection.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo1 hour ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo1 hour ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo1 hour ago
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo1 hour ago
Radian (RDN) Up 1.5% Since Last Earnings Report: Can It Continue?
Yahoo1 hour ago